Erste Group downgraded Regeneron to Hold from Buy. The company recently suffered a preliminary court defeat in a legal dispute with Amgen, which means Amgen can sell Eleya, for which Regeneron claims patents. Regeneron’s sales growth will be impaired as a result, as will the upside potential of the shares, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron, Sanofi announce Dupixent approved in U.S. for COPD patients
- Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
- Biotech Alert: Searches spiking for these stocks today
- Morgan Stanley backs Overweight on Regeneron after Amgen temporarily enjoined
- Closing Bell Movers: Micron rallies 13% after Q4 earnings beat